Hematology/Oncology

Top Story

Daratumumab-based triplet regimen extends PFS in advanced multiple myeloma

Daratumumab-based triplet regimen extends PFS in advanced multiple myeloma
December 15, 2019
Meeting NewsPerspective

Residual cancer burden predicts long-term outcomes across breast cancer subtypes

December 13, 2019
SAN ANTONIO — Residual cancer burden after neoadjuvant chemotherapy accurately predicted long-term recurrence risk and survival across all breast cancer subtypes…
Meeting NewsPerspective

Complete response, minimal residual disease negativity linked to lower relapse risk in relapsed/refractory AML

December 13, 2019
ORLANDO — Achieving complete remission and minimal residual disease negativity appeared to be independently associated with reduced cumulative incidence of relapse…
Meeting NewsPerspective

Menopausal hormone therapy regimens have opposite lasting effects on breast cancer incidence

December 13, 2019
SAN ANTONIO — Two common hormone therapy regimens had opposite long-term effects on breast cancer incidence among postmenopausal women, according to results from…
Meeting News

Melflufen, dexamethasone demonstrate long-term OS benefits in multiple myeloma

December 13, 2019
ORLANDO — Treatment with melflufen and dexamethasone led to sustained long-term overall survival among patients with relapsed/refractory multiple myeloma…
More Headlines »
CME ABIM MOC

Ace the Case: A 54-year-old Man With 2 Weeks of Progressive Shortness of Breath

There is no commercial support for this activity.

This educational activity will utilize a case study to discuss the management of a 54-year-old man with 2 weeks of…
More »
Video
Meeting News

Early steroid use may reduce CAR T-cell treatment-related toxicity in aggressive lymphoma

December 12, 2019
More »
Resource Centers
European Society for Medical Oncology Congress

European Society for Medical Oncology Congress

CME

2019 Texas Oncology Clinical Educational Symposium

This activity is supported by educational grants from AbbVie, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Takeda Oncology; and Verastem, Inc..

Clinical outcomes for advanced cancers continue to improve through the identification as well as the development of…
More »
Current Issues
View the Current Issue
HemOnc Today Cell Therapy Next